128 related articles for article (PubMed ID: 27648143)
1. Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients.
Collina F; Cerrone M; Peluso V; Laurentiis MD; Caputo R; Cecio RD; Liguori G; Botti G; Cantile M; Bonito MD
Am J Transl Res; 2016; 8(8):3530-9. PubMed ID: 27648143
[TBL] [Abstract][Full Text] [Related]
2. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
4. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
[TBL] [Abstract][Full Text] [Related]
9. LncRNA
Collina F; Aquino G; Brogna M; Cipolletta S; Buonfanti G; De Laurentiis M; Di Bonito M; Cantile M; Botti G
J Cancer; 2019; 10(9):2018-2024. PubMed ID: 31205562
[TBL] [Abstract][Full Text] [Related]
10. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
Safarpour D; Tavassoli FA
Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
13. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Goto W; Tanaka S; Morisaki T; Takashima T; Noda S; Onoda N; Ohsawa M; Hirakawa K; Ohira M
Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28067809
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria.
Liman AA; Kabir B; Abubakar M; Abdullahi S; Ahmed SA; Shehu SM
Niger J Clin Pract; 2022 Jan; 25(1):97-104. PubMed ID: 35046202
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor status is highly conserved during tumor progression of breast cancer.
Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
[TBL] [Abstract][Full Text] [Related]
16. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
[TBL] [Abstract][Full Text] [Related]
17. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.
Mansouri H; Alcaraz LB; Mollevi C; Mallavialle A; Jacot W; Boissière-Michot F; Simony-Lafontaine J; Laurent-Matha V; Roger P; Liaudet-Coopman E; Guiu S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429078
[TBL] [Abstract][Full Text] [Related]
18. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
19. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
20. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
